Press
NeuroLight Awarded a Patent for Groundbreaking Neuromodulation Technology
US Patent No. 11,413,425 is issued for non-pharmaceutical treatment of coronasomnia with neuromodulation POMONA, NEW YORK, UNITED STATES, January 31, 2024 — NeuroLight, Inc. today announced the recent grant of US Patent No. 11,413,425 for the treatment of coronasomnia with neuromodulation. This patent covers a novel method of
US Patent Granted to NeuroLight for Technology to Induce Sleep by Neuromodulation
NeuroLight Aims to Use its Technology for Transplanting Mental States to Treat Insomnia and Other Sleep Disorders POMONA, NEW YORK, USA, January 11, 2024 — NeuroLight, Inc., a leading innovator in the field of neuromodulation, is thrilled to announce the recent grant of a United
NeuroLight Has Been Awarded another US Patent on Technology to Enhance Emotional Response
NeuroLight, a neuromodulation company, first to develop technology for transplanting brain states, received a patent on technology to enhance emotional response
NeuroLight Has Been Awarded US Patent on Technology to Enhance Emotional Response
Pomona, N.Y., August 10, 2023—NeuroLight, Inc., a neuromodulation company, announced that it was awarded a US patent on the technology to enhance emotional response. US Patent No. 11,318,277, titled “Method and apparatus for neuroenhancement to enhance emotional response,” was issued to Neuroenhancement Lab, LLC, the
NeuroLight Awarded Competitive Grant from the U.S. National Science Foundation
NeuroLight, Inc., a neuromodulation company first to develop technology for transplanting mental states™, awarded grant from the U.S. National Science Foundation (NSF)
Neuroenhancement Lab, Inc. Announces Rebrand as NeuroLight
Neuroenhancement Lab, Inc., a neuromodulation company first to develop technology for transplanting mental states™ from one person to another, rebrands itself as NeuroLight.
Parisa Khosropour Joins Advisory Board of Neuroenhancement Lab, Inc.
Suffern, N.Y., February 25, 2018—Neuroenhancement Lab, Inc., a neuromodulation company headquartered in Suffern, NY, announced today that Parisa Khosropour joined its Advisory Board. As a pioneer in neuromodulation, Neuroenhancement Lab is the first company to develop technology for transplanting mental state™ from one person to
